The lactate dehydrogenase (LDH) release assay showed that YARS significantly promoted LDH release up to 3.5-fold (Fig. 3b), and FACS analysis demonstrated 8- to 20-fold increases in PI-positive populations, which consistently indicated that YARS damaged the plasma membrane in breast cancer cells (Fig. 3c). This evidence concerns the gene YARS1 and breast carcinoma.